1800-272-662
Shopping Cart 0
countryflagAU
Login

Kalvista Pharmaceuticals Inc

Healthcare US KALV

16.94USD
-0.44(2.53%)

Last update at 2026-03-13T20:00:00Z

Day Range

16.4718.20
LowHigh

52 Week Range

7.2116.88
LowHigh

Fundamentals

  • Previous Close 17.38
  • Market Cap471.03M
  • Volume844041
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-107.15200M
  • Revenue TTM3.82M
  • Revenue Per Share TTM0.21
  • Gross Profit TTM -80.27600M
  • Diluted EPS TTM-3.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Income before tax -92.90700M -82.33900M -46.24400M -29.24000M -20.69200M
Minority interest - - - - -
Net income -74.85300M -68.51200M -44.49400M -29.11600M -20.81600M
Selling general administrative 30.59M 26.45M 16.64M 13.03M 10.93M
Selling and marketing expenses - - - - -
Gross profit - - 12.69M 12.69M 16.13M
Reconciled depreciation 0.72M 0.56M 0.54M 0.51M 0.38M
Ebit -110.87100M -96.61300M -57.92300M -40.53300M -29.86900M
Ebitda -110.24300M -94.51200M -58.23300M -39.65400M -29.49100M
Depreciation and amortization 0.63M 2.10M -0.31000M 0.88M 0.38M
Non operating income net other 17.96M 14.27M 11.68M 11.29M 9.13M
Operating income -110.87100M -96.61300M -57.92300M -40.53300M -29.82000M
Other operating expenses 110.87M 96.61M 57.92M 53.22M 45.95M
Interest expense -17.96400M 1.09M 0.90M 10.93M 9.18M
Tax provision 0.00000M 0.00000M 0.00000M -0.12400M 0.12M
Interest income 2.23M 1.09M 0.90M 1.83M 1.40M
Net interest income 2.23M 1.09M 0.90M 1.83M 1.40M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -18.05400M -13.82700M -1.75000M -0.12400M 0.12M
Total revenue 0.00000M 0.00000M 12.69M 12.69M 16.13M
Total operating expenses 110.87M 96.61M 57.92M 53.22M 45.95M
Cost of revenue - - - - 35.02M
Total other income expense net 17.96M 14.27M 11.68M 11.29M 7.73M
Discontinued operations - - - - -
Net income from continuing ops -92.90700M -82.33900M -46.24400M -29.11600M -20.81600M
Net income applicable to common shares -92.90700M -82.33900M -46.24400M -29.11600M -20.81600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Total assets 183.20M 203.88M 272.01M 92.53M 118.13M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.38M 10.64M 4.92M 4.46M 3.42M
Total liab 22.18M 18.79M 14.82M 8.78M 21.39M
Total stockholder equity 161.03M 185.09M 257.19M 83.75M 96.74M
Deferred long term liab - - - - -
Other current liab 9.13M 6.96M 6.93M 5.46M 5.59M
Common stock 0.03M 0.03M 0.02M 0.02M 0.02M
Capital stock 0.03M 0.03M 0.02M 0.02M 0.02M
Retained earnings -343.08200M -250.17500M -167.83600M -121.59200M -92.47600M
Other liab - - - - 3.34M
Good will - - - - -
Other assets - 0.19M 0.20M 0.18M 0.17M
Cash 56.24M 30.73M 50.59M 15.79M 32.01M
Cash and equivalents - - - - -
Total current liabilities 15.03M 11.58M 9.77M 7.72M 18.05M
Current deferred revenue - - - - 9.54M
Net debt -48.00600M -22.54400M -44.68300M -14.14400M -31.95200M
Short term debt 1.09M 0.98M 0.86M 0.59M 0.05M
Short long term debt - - - - -
Short long term debt total 8.23M 8.19M 5.91M 1.65M 0.05M
Other stockholder equity 507.13M 439.10M 426.44M 207.21M 191.12M
Property plant equipment 2.95M 2.18M 1.79M 2.04M 2.41M
Total current assets 172.33M 193.65M 264.26M 88.70M 115.55M
Long term investments - - - - -
Net tangible assets 161.03M 185.09M 257.19M 83.75M 96.74M
Short term investments 93.14M 135.47M 198.34M 51.92M 68.81M
Net receivables 16.57M 14.10M 10.42M 16.53M 11.31M
Long term debt - - - - -
Inventory - 2.71M - - -
Accounts payable 4.82M 3.64M 1.98M 1.68M 2.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.06000M -3.86100M -1.43200M -1.88200M -1.92600M
Additional paid in capital - - - - -
Common stock total equity 0.03M 0.03M 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity -343.08200M -250.17500M -167.83600M -121.59200M -92.47600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.11M 0.19M 0.20M 0.18M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 10.88M 10.23M 7.75M 3.83M 2.59M
Capital lease obligations 8.23M 8.19M 5.91M 1.65M 0.05M
Long term debt total - - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Investments 42.61M 58.79M -147.57200M 16.97M -68.34100M
Change to liabilities 3.04M 2.16M 1.13M -1.05200M 4.20M
Total cashflows from investing activities 41.41M 57.86M -147.65400M 16.75M -69.42200M
Net borrowings - - - -0.05400M -0.20900M
Total cash from financing activities 58.12M 1.58M 212.12M 11.58M 87.94M
Change to operating activities - -14.00900M 8.20M -6.94600M -4.19700M
Net income -92.90700M -82.33900M -46.24400M -29.11600M -20.81600M
Change in cash 25.51M -19.86000M 34.80M -16.21700M -19.04900M
Begin period cash flow 30.73M 50.59M 15.79M 32.01M 51.05M
End period cash flow 56.24M 30.73M 50.59M 15.79M 32.01M
Total cash from operating activities -75.26100M -78.13400M -30.17100M -44.81600M -36.36500M
Issuance of capital stock 56.58M 0.00000M 210.58M 11.42M 87.91M
Depreciation 0.72M 0.56M 0.54M 0.51M 0.38M
Other cashflows from investing activities - - - 16.97M -68.34100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - 7.46M - -
Sale purchase of stock 58.12M 1.58M 212.12M 11.64M 88.15M
Other cashflows from financing activities 1.53M 1.58M 1.53M 0.22M 0.24M
Change to netincome 8.44M 13.22M 6.39M 4.22M 2.86M
Capital expenditures 1.20M 0.93M 0.08M 0.22M 1.08M
Change receivables - - - - -
Cash flows other operating 4.46M -14.30200M 7.33M -19.57500M -22.98900M
Exchange rate changes - - - - -1.20500M
Cash and cash equivalents changes 24.27M -18.69300M 34.29M -16.47900M -19.04900M
Change in working capital 7.41M -12.32200M 8.35M -20.64000M -18.79000M
Stock based compensation 9.92M 11.09M 7.12M 4.45M 2.97M
Other non cash items 0.08M 4.88M 0.11M 0.01M -0.10300M
Free cash flow -76.45700M -79.06500M -30.25300M -45.03600M -37.44600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KALV
Kalvista Pharmaceuticals Inc		 -0.44 2.53% 16.94 - - 107.42 5.66 76.33 -3.5261
NVO
Novo Nordisk A/S		 -0.06 0.16% 37.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.315 0.82% 38.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -8.79 1.84% 469.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.84 0.11% 745.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Kalvista Pharmaceuticals Inc

55 Cambridge Parkway, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Thomas Andrew Crockett M.B.A. CEO & Director 1975
Mr. Benjamin L. Palleiko Chief Bus. Officer & CFO 1966
Dr. Christopher M. Yea Ph.D. Chief Devel. Officer 1964
Dr. Edward P. Feener Ph.D. Chief Scientific Officer 1960
Jarrod Aldom VP of Corp. Communications NA
Ms. Rachel M. Morten Sr. VP of Regulatory Affairs & QA NA
Dr. Michael D. Smith Pharm.D. Sr. VP of Devel. 1979
Dr. Paul K. Audhya M.B.A., M.D. Chief Medical Officer 1972
Mr. Stephen Donnelly Director of Fin. and Company Sec. NA
Mr. John B. McKune VP of Fin. 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.